cas 14769-73-4 99 % Levamisole powder

Details:

cas 14769-73-4 99 % Levamisole powder 

Levamisole is the L-isomer of tetramisole and is more active than the racemic mixture.  It was introduced in 1966 as a veterinary drug and a little later as a human anthelminthic drug against ascariasis.  The drug has also shown to be effective against hookworms (Ancylostoma duodenale and Necator americanus)  [1].  The mechanism of action of levamisole in helminthiasis is through its stimulation of autonomic ganglia (nicotinic receptors) of the worms.  On exposure to the drug, immature and adult worms show spastic contraction followed by tonic paralysis.  This mechanism seems to be common to other anthelminthics such as pyrantel and bephenium hydroxynaphthoate [2].  In higher doses, levamisole acts as an immunostimulant.  It restores depressed cell-mediated immune mechanisms in peripheral T-lymphocytes, but may have marginal effects in immunologically competent individuals [3].

 
Levimasole  function 

Levamisole is used for initial and secondary immunodeficient conditions, autoimmune diseases, chronic and reoccurring infections, large intestine adenocarcinoma, helmintosis, and rheumatoid arthritis.  

Levimasole is also a drug of choice for ascardiasis. Numerous investigations show that a single dose of levamisole heals from 90 to 100% of patients with ascardiasis, in particular those infected with A. duodenale. It is less effective against ancylostomiasis and strongyloidiasis. However, it is not effective against N. americanus. It seems likely that it has a gangliostimulating effect on parasite tissues in both the parasympathetic and sympathetic regions. Moreover, it is presumed that this drug has an immunomodulatory effect on the host organism.